- ￥2300 - 6000
- MedChemExpress(MCE)
- 美国
- HY-101833
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
4°C, sealed storage, away from moisture
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
131888-54-5
- 规格：
10 mM * 1 mL/1 mg/5 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥ |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥2300.0 |
| 规格： | 5 mg | 产品价格： | ￥6000.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
YM-264
CAS No. : 131888-54-5
MCE 国际站：YM-264
产品活性：YM-264 是一种有口服活性的、血小板活化因子 (PAF) 的有效选择性拮抗剂，其在兔子血小板膜上的 pKi 值为 8.85。
研究领域：GPCR/G Protein
作用靶点：Platelet-activating Factor Receptor (PAFR)
In Vitro: The anti-platelet-activating factor effect of YM-264 is examined in vitro. YM-264 inhibits [3H] platelet-activating factor binding to rabbit platelet membranes with a pKivalue of 8.85. YM-264 inhibits the platelet-activating factor-induced human, rabbit and guinea-pig platelet aggregation with pA2 values of 8.68, 8.33 and 8.14, respectively.
In Vivo: There are no significant differences in baseline airway responsiveness between control and YM-264 treated groups. Airway hyperresponsiveness induced by antigen exposure is significantly inhibited by the administration of YM-264. The baseline Rrs is 0.40 (0.02) cm H2O/mL/s in the control group (n=6). In the YM-264 treated groups, the baseline Rrs is 0.39 (0.01) and 0.36 (0.01) cm H2O/mL/s at a doses of 1 mg/kg (n=5) and 3 mg/kg (n=6), respectively. The Rrs during the IAR significantly increase from baseline to 0.92 (0.10) cm H2O/mL/s in control (p=0.0002), 0.81 (0.12) in YM-264 1 mg/kg (p=0.01), and 1.06 (0.29) in YM-264 3 mg/kg (p=0.048). Reelevation of Rrs in the late phase is observed in the control group after antigen challenge. At this phase, Rrs significantly increase to 0.72 (0.10) cm H2O/mL/s (p=0.0101) from the baseline (0.40) at 6 h after the exposure of antigen. In contrast, YM-264 at the doses of 1 and 3 mg/kg show significant inhibition of reelevation of Rrs as compared with control. YM-264 inhibit the eosinophil infiltration dose dependently.
相关产品：Apafant | CV-6209 | Foropafant | TCV-309 chloride | (+)-Guaiacin | 6-Methoxydihydroavicine | Epiyangambin | Homoeriodictyol 7-O-β-D-glucoside | Israpafant | Kadsurenin B | Kadsurenone | Kadsurin A | L-659,989 | Lexipafant | Modipafant | N-Acetyldesloratadine | Pinusolidic acid | Piperulin A | Pregomisin | Ro 19-1400 | Ro-24-0238 | Ro-24-4736 | Scandenolide | SDZ-62-434 | Setipafant | Tulopafant | 48740 RP | E-6123 | PAF-AN-1
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验细胞增殖分化及抗体产生。 (2)IL-19：诱导单核细胞产生IL-6和TNF-a，并可诱导细胞凋亡和单核细胞中的活性氧中间物(ROS)的产生；与正常对照小鼠相比，在BALB／CJ鼠的哮喘模型中IL-19高表达，并诱导活化T细胞产生IL-4、IL-5、IL-10和IL-13等Th2细胞因子。 (3)IL-20：LPS可诱导原代培养的神经胶质细胞以及RAW264．7巨噬细胞系表达IL-20，在大脑的感染中发挥作用；IL-20可以选择性地促进CD34多能祖
-1:5000的稀释度，用1%BSA-PBS（含0.05%TWEEN20）稀释 ④ 显色底物缓冲液 A.HRP标记二抗底物缓冲液 DAB KIT（KPL LOT NO YM107 CAT：54-10-00）, Tris Buffer 3滴，DAB Substrate 3滴,Peroxide solution 2滴于5ml蒸馏水中，避光，混匀 B.AKP标记二抗底物缓冲液 AKP缓冲液： 0.1mol/L Tris-HCL（PH9.5）, 0.1mol/L NaCL
. [10]Collins FS,Guyer MS,Charkravarti A.Variation on a theme; cataloging human DNA sequnce variation[J].Science,1997, 278:1580-1581. [11]Dib C,Faure S,Fizames C,etal.A comprehensive genetic map of the human genome based on 5,264microsatellite.Nature
技术资料暂无技术资料 索取技术资料
